Pre-Open Movers 07/30: (ERYP) (TEAM) (MSON) Higher; (PINS) (ZYXI) (AMZN) Lower (more...)
Get Alerts ERYP Hot Sheet
Join SI Premium – FREE
Pre-Open Stock Stock Movers:
ERYTECH Pharma (Nasdaq: ERYP) 99% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).
Pinterest (NYSE: PINS) 20% LOWER; reported Q2 EPS of $0.25, $0.12 better than the analyst estimate of $0.13. Revenue for the quarter came in at $613 million versus the consensus estimate of $561.88 million. Global Monthly Active Users (MAUs) grew 9% year over year to 454 million. Engagement headwinds on Pinterest have continued in July. As of July 27, 2021, U.S. MAUs have declined approximately 7% and global MAUs have grown approximately 5% year over year*.
Atlassian (NASDAQ: TEAM) 14% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.
Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.
Capri Holdings Limited (NYSE: CPRI) 9% HIGHER; reported Q1 EPS of $1.42, $0.63 better than the analyst estimate of $0.79. Revenue for the quarter came in at $1.25 billion versus the consensus estimate of $1.11 billion. Capri Holdings Limited sees FY2022 EPS of $4.50, versus the consensus of $3.93. Capri Holdings Limited sees FY2022 revenue of $5.3 billion, versus the consensus of $5.17 billion.
Zynex, Inc. (NASDAQ: ZYXI) 8.2% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.
Amazon (NASDAQ: AMZN) 7% LOWER; reported Q2 EPS of $15.12, $2.90 better than the analyst estimate of $12.22. Revenue for the quarter came in at $113.1 billion versus the consensus estimate of $115.07 billion. Amazon sees Q3 2021 revenue of $106-112 billion, versus the consensus of $118.6 billion.
Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.
Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.
DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fusion Pharmaceuticals (FUSN) Acquired by AstraZeneca (AZN) for $21/sh Cash + $3 CVR
- Dril-Quip (DRQ) and Innovex to Combine
- Pfizer (PFE) to trim its Haleon stake to 24%
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!